

Date of the CVA	20/05/2019
-----------------	------------

Section A. PERSONAL DATA

Name and Surname	Juan Carlos Rodríguez Manzaneque Escribano		
DNI	06234359W	Age	50
Researcher's identification number	Researcher ID	F-3899-2012	
	Scopus Author ID		
	ORCID	0000-0001-5951-7029	

A.1. Current professional situation

Institution	FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD		
Dpt. / Centre	Oncología Genómica / GENYO. Centro de Genómica e Investigación Oncológica: Pfizer/Universidad de Granada/Junta de Andalucía		
Address	Avda. de la Ilustración, 114, PTS-Granada, 18016, Granada		
Phone	(+34) 697958316	Email	juancarlos.rodriguez@genyo.es
Professional category	Principal Investigator	Start date	2008
UNESCO spec. code	240300 - Biochemistry; 240700 - Cell biology; 241007 - Human genetics; 320703 - Carcinogenesis; 320713 - Oncology		
Keywords	Biomedicine; Cell biology		

A.2. Academic education (Degrees, institutions, dates)

Bachelor/Master/PhD	University	Year
Bioquímica y Biología Molecular, Facultad de Farmacia	Universidad Complutense de Madrid	1996
Licenciado en Farmacia	Universidad Complutense de Madrid	1991

A.3. General quality indicators of scientific production

Citation metrics according to ResearcherID (F-3899-2012)

Total articles in publication list: **32**
 Articles with citation data: **30**
 Sum of the times cited: **1765**
 Average citations per article: **58.83**
 h-index: **18**
 Last updated: **02/25/2019 11:08 GMT**

Section B. SUMMARY OF THE CURRICULUM

Section C. MOST RELEVANT MERITS (ordered by typology)

C.1. Publications

- Scientific paper.** 2018. ADAMTS1 protease is required for a balanced immune cell repertoire and tumour inflammatory response *Scientific Reports*. 8-1.
- Scientific paper.** Prieto, C; et al. 2018. NG2 Antigen is involved in Leukemia Invasiveness and Central Nervous System Infiltration in MLL-rearranged Infant B-ALL Leukemia. 32-3, pp.633-644.
- Scientific paper.** Fernández-Rodríguez R; et al. 2016. Stroma-derived but not tumor ADAMTS1 is a main driver of tumor growth and metastasis *Oncotarget*. 7-23, pp.34507-34519. ISSN 1949-2553.
- Scientific paper.** Santos-Oliveira P; et al. 2015. The Force at the Tip - Modelling Tension and Proliferation in Sprouting Angiogenesis. *PLoS Computational Biology*. 11-8, pp.e1004436.

- 5 **Scientific paper.** Rodríguez-Manzaneque, JC; et al. 2015. ADAMTS proteases in vascular biology *Matrix Biology*. 44-46, pp.38-45.
- 6 **Scientific paper.** Martino-Echarri E; et al. 2014. Relevance of IGFBP2 proteolysis in glioma and contribution of the extracellular protease ADAMTS1 *Oncotarget*. 5-12, pp.4295-4304. ISSN 1949-2553.
- 7 **Scientific paper.** Barrientos-Durán A; et al. (/56). 2014. Carboxyl modified single-wall carbon nanotubes improve bone tissue formation in vitro and repair in a rat model *International Journal of Nanomedicine*. 9, pp.4277.
- 8 **Scientific paper.** Rodríguez MI; et al. (/1.014). 2013. PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation. *PLoS Genetics*. 9-6, pp.e1003531. ISSN 1553-7390.
- 9 **Scientific paper.** Martino-Echarri, Estefanía; et al. (/1.111). 2013. Contribution of ADAMTS1 as a tumor suppressor gene in human breast carcinoma. Linking its tumor inhibitory properties to its proteolytic activity on nidogen-1 and nidogen-2 *International Journal of Cancer*. 133-10, pp.2315-2324. ISSN 1097-0215.
- 10 **Scientific paper.** Bueno-Uroz, Clara; et al. (/1.415). 2012. A human ESC model for MLL-AF4 leukemic fusion gene reveals an impaired early hematopoietic-endothelial specification. *CELL RESEARCH*. 22-6, pp.986-1002.
- 11 **Scientific paper.** Travasso, R.D.; et al. (/45). 2011. Tumor angiogenesis and vascular patterning: a mathematical model. *PLOS ONE*. 6-5, pp.e19989.
- 12 **Scientific paper.** Casal-Moreno, Carmen; et al. (/88). 2010. ADAMTS1 CONTRIBUTES TO THE ACQUISITION OF AN ENDOTHELIAL-LIKE PHENOTYPE IN PLASTIC TUMOR CELLS. *Cancer Research*. 70-11, pp.4676-4686.
- 13 **Scientific paper.** Esselens-,Cary; et al. (/57). 2010. THE CLEAVAGE OF SEMAPHORIN 3C INDUCED BY ADAMTS1 PROMOTES CELL MIGRATION *The Journal of biological chemistry (Print)*. 285-4, pp.2463-2473.
- 14 **Scientific paper.** Reynolds-,L.E.; et al. (/923). 2010. TUMOUR ANGIOGENESIS IS REDUCED IN THE TC1 MOUSE MODEL OF DOWN'S SYNDROME *Nature (London)*. 465-7299, pp.813-817.
- 15 **Scientific paper.** Rodríguez-Manzaneque-Escribano, Juan Carlos; et al. (/18). 2009. CLEAVAGE OF SYNDECAN-4 BY ADAMTS1 PROVOKES DEFECTS IN ADHESION. *International journal of biochemistry & cell biology*. 41-4, pp.800-810.
- 16 **Scientific paper.** Torres-Collado-, Ax; et al. 2006. ADAMTS1 INTERACTS WITH, CLEAVES, AND MODIFIES THE EXTRACELLULAR LOCATION OF THE MATRIX INHIBITOR TISSUE FACTOR PATHWAY INHIBITOR-2. *The Journal of biological chemistry (Print)*. 281-26, pp.17827-17837.
- 17 **Scientific paper.** Canals, F; et al. 2006. IDENTIFICATION OF SUBSTRATES OF THE EXTRACELLULAR PROTEASE ADAMTS1 BY DIGE PROTEOMIC ANALYSIS. *Proteomics (Weinheim. Print)*. 6-SUPP, pp.S28-S35.
- 18 **Scientific paper.** Lee-,Nv; et al. 2005. FIBULIN-1 ACTS AS A COFACTOR FOR THE MATRIX METALLOPROTEASE ADAMTS-1. *The Journal of biological chemistry (Print)*. 280-41, pp.34796-34804.
- 19 **Scientific paper.** Rodríguez-Manzaneque-Escribano, Juan Carlos; et al. 2002. ADAMTS1 CLEAVES AGGRECAN AT MULTIPLE SITES AND IS DIFFERENTIALLY INHIBITED BY METALLOPROTEINASE INHIBITORS. *Biochemical and biophysical research communications (Print)*. 293-1, pp.501-508.
- 20 **Scientific paper.** Rodríguez-manzaneque, Juan Carlos; et al. 2001. THROMBOSPONDIN-1 SUPPRESSES SPONTANEOUS TUMOR GROWTH AND INHIBITS ACTIVATION OF MATRIX METALLOPROTEINASE-9 AND MOBILIZATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR. *Proceedings of the National Academy of Sciences of the United States of America*. 98-22, pp.12485-12490.
- 21 **Scientific paper.** Sandy-,Jd; et al. 2001. VERSICAN V1 PROTEOLYSIS IN HUMAN AORTA IN VIVO OCCURS AT THE GLU441-ALA442 BOND, A SITE THAT IS CLEAVED BY RECOMBINANT ADAMTS-1 AND ADAMTS-4. *The Journal of biological chemistry (Print)*. 276-16, pp.13372-13378.

- 22 **Scientific paper.** Rodríguez-manzaneque, Juan Carlos; et al. 2000. CHARACTERIZATION OF METH-1/ADAMTS1 PROCESSING REVEALS TWO DISTINCT ACTIVE FORMS. The Journal of biological chemistry (Print). 275-43, pp.33471-33479.
- 23 **Scientific paper.** Rodríguez-manzaneque, Juan Carlos; Graubert-,M; Iruela-Arispe-,MI. 2000. ENDOTHELIAL CELL DYSFUNCTION FOLLOWING PROLONGED ACTIVATION OF PROGESTERONE RECEPTOR. Human reproduction (Oxford. Print). 15-SUPP 3, pp.39-47.
- 24 **Scientific paper.** Iruela-Arispe-,MI; Rodríguez-manzaneque, Juan Carlos; Abu-Jawdeh-,G. 1999. ENDOMETRIAL ENDOTHELIAL CELLS EXPRESS ESTROGEN AND PROGESTERONE RECEPTORS AND EXHIBIT A TISSUE SPECIFIC RESPONSE TO ANGIOGENIC GROWTH FACTORS. MICROCIRCULATION. 6-2, pp.127-140.
- 25 **Scientific paper.** Rodríguez-manzaneque, Juan Carlos; et al. 1999. PROGESTERONE REGULATES PROLIFERATION OF ENDOTHELIAL CELLS. The Journal of biological chemistry (Print). 274-4, pp.2185-2192.
- 26 **Scientific paper.** Rodríguez-manzaneque, Juan Carlos; Pérez-Castillo-,A; Santos-,A. 1998. CONTROL BY THYROID HORMONE OF NGFI-A GENE EXPRESSION IN LUNG: REGULATION OF NGFI-A PROMOTER ACTIVITY. Molecular and cellular endocrinology (Print). 141-1-2, pp.101-110.
- 27 **Scientific paper.** Moreno-,Beatriz; et al. 1997. THYROID HORMONE CONTROLS THE EXPRESSION OF INSULIN-LIKE GROWTH FACTOR I RECEPTOR GENE AT DIFFERENT LEVELS IN LUNG AND HEART OF DEVELOPING AND ADULT RATS. Endocrinology (Philadelphia). 138-3, pp.1194-1203.
- 28 **Scientific paper.** Bonnin-,Ana; et al. 1994. CHANGES IN TYROSINE HYDROXYLASE GENE EXPRESSION IN MESENCEPHALIC CATECHOLAMINERGIC NEURONS OF IMMATURE AND ADULT MALE RATS PERINATALLY EXPOSED TO CANNABINOIDS. Developmental brain research. 81-1, pp.147-150.
- 29 **Scientific paper.** Castelló-,A; et al. 1994. PERINATAL HYPOTHYROIDISM IMPAIRS THE NORMAL TRANSITION OF GLUT4 AND GLUT1 GLUCOSE TRANSPORTERS FROM FETAL TO NEONATAL LEVELS IN HEART AND BROWN ADIPOSE TISSUE. EVIDENCE FOR TISSUE-SPECIFIC REGULATION OF GLUT4 EXPRESSION BY THYROID HORMONE. The Journal of biological chemistry (Print). 269-8, pp.5905-5912.
- 30 **Book chapter.** Rodríguez-Baena FJ; et al. 2018. Evaluation of tumor vasculature using a syngeneic tumor model in wild type and genetically modified mice Proteases and Cancer: Methods and Protocols (Methods in Molecular Biology. Springer-Nature. 1731, pp.179-192.
- 31 **Book chapter.** Quinas-Guerra MM; et al. 2012. Understanding the Dynamics of Tumor Angiogenesis: A Systems Biology Approach Systems Biology in Cancer Research and Drug Discovery. Springer Netherlands. pp.197-227.

C.2. Participation in R&D and Innovation projects

- 1 Estudio del microentorno extracelular en melanoma: en busca de nuevas herramientas para una medicina personalizada Consejería de Salud. Proyectos Estratégicos I+D+i con incorporación de capital humano. (FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD). 01/01/2019-31/12/2022.
- 2 Papel modulador de la proteasa extracelular ADAMTS1 en melanoma Instituto de Salud Carlos III. Juan Carlos Rodríguez-Manzaneque Escribano. (FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD). 01/01/2017-31/12/2019.
- 3 PEJ-2014-A-38416, CancerLab: del cultivo celular al animal al modelo humano Ministerio de Economía y Competitividad. Promoción de Empleo Joven e Implantación de la Garantía Juvenil 2014. (FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD). 11/2015-10/2018.
- 4 Elucidando la contribución de la proteasa ADAMTS1 en neo-vascularización y plasticidad tumoral Instituto de Salud Carlos III. Juan Carlos Rodríguez-Manzaneque Escribano. (FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD). 01/01/2014-31/12/2016.

- 5 Estudio Experimental y teórico del papel del microentorno extracelular en mecanismos de neo-vascularización y angiogénesis. Consejería de Economía, Innovación Y Ciencia. Juan Carlos Rodríguez-Manzaneque Escribano. (FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD). 02/2011-02/2015.
- 6 Papel de la proteasa extracelular ADAMTS1 en plasticidad tumoral y en fenómenos de neo-vascularización. Instituto de Salud Carlos III. Juan Carlos Rodríguez-Manzaneque Escribano. (FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD). 01/2011-12/2013.
- 7 Papel de la proteasa extracelular ADAMTS1 en plasticidad tumoral y metástasis Ministerio de Ciencia e Innovación. Investigación. Juan Carlos Rodríguez-Manzaneque Escribano. (FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD). 01/2010-12/2010.
- 8 SAF2006-04019, CARACTERIZACIÓN DE LA ACTIVIDAD CATALÍTICA DE LA METALOPROTEASA ADAMTS1 Y SU RELEVANCIA EN PROCESOS TUMORIGÉNICOS Y METASTÁSICOS. MINISTERIO DE EDUCACION Y CIENCIA. OTROS PROGRAMAS DEL PLAN NACIONAL I+D, MINISTERIO DE CIENCIA Y TECNOLOGÍA. JUAN CARLOS RODRÍGUEZ-MANZANEQUE ESCRIBANO. (FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD). From 01/10/2006. 163.350 €.
- 9 052510, CLEAVAGE OF PROTEOGLYCAN BY ADAMTS PROTEASES AND ITS IMPLICATIONS ON ANGIOGENESIS AND METASTATIC PROCESSES. Fundació La Marató de TV3. OTROS PROGRAMAS, ORGANISMOS PRIVADOS (EXTERNOS). JUAN CARLOS RODRÍGUEZ-MANZANEQUE ESCRIBANO. From 01/05/2006. 248.733 €.
- 10 CARACTERIZACIÓN DE TFPI-2 COMO MODULADOR DEL REMODELAMIENTO EXTRACELULAR: RELEVANCIA DE SU INTERACCIÓN CON LA METALOPROTEASA ADAMTS1. OTROS PROGRAMAS DEL PLAN NACIONAL I+D, MINISTERIO DE CIENCIA Y TECNOLOGÍA. JUAN CARLOS RODRÍGUEZ-MANZANEQUE ESCRIBANO. From 01/12/2002. 121.900 €.

C.3. Participation in R&D and Innovation contracts

C.4. Patents